TrialNeuro-oncology2023

Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.

Santhosh A Upadhyaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.